Small molecule · developed by Oculis
OCS-01 is a dexamethasone ophthalmic suspension, 1.5%, studied for inflammation and eye pain and for postoperative cataract.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06128369 | Phase 3 | Inflammation Eye Pain | Terminated | OCS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Inflammation Eye PainPostoperative Cataract
Updated Oct 25, 2026. Something wrong or missing? Report it on the OCS page.
See OCS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OCS catalysts and pipeline →